In the second quarter, we continued to make substantial progress on our strategic growth initiatives to drive sustained and profitable growth, and we further solidified our position as the leader in the aortic disease space. Learn more about our second quarter results today by visiting: https://bit.ly/4drYboU #Artivion #CardioVascular
Artivion APAC
Biotechnology Research
Kennesaw, GA 2,686 followers
Advancing Aortic Technologies with Purpose™
About us
Artivion is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. Our purpose is to develop simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with diseases of the aorta and deliver breakthrough technologies of unsurpassed quality that have far-reaching impact. Our decades of expertise in treating aortic diseases—coupled with our recent acquisitions and partnerships—have empowered us to offer cardiac and vascular surgeons a suite of aortic-centric solutions such as cryopreserved cardiac and vascular allografts, surgical sealants, prosthetic heart valves, aortic stents, and stent-grafts. Artivion has over 1,250 employees worldwide with sales representation in over 100 countries. The Company has manufacturing facilities located in Atlanta, Georgia, Austin, Texas and Hechingen, Germany. Additionally, it has sales and distribution offices in various countries throughout Europe, Asia, and South America
- Website
-
http://www.artivion.com
External link for Artivion APAC
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Kennesaw, GA
- Type
- Public Company
- Founded
- 1984
Locations
-
Primary
Get directions
Kennesaw, GA 30144, US
Employees at Artivion APAC
Updates
-
Join us today, August 8th, for our teleconference call and live webcast at 4:30 p.m. ET to discuss the Q2 financial results, followed by a question and answer session hosted by Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion. Learn more today: https://bit.ly/4dgMPnY
-
Join us tomorrow, August 8th, for our teleconference call and live webcast at 4:30 p.m. ET to discuss the Q2 financial results, followed by a question and answer session hosted by Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion. Learn more today: https://bit.ly/4dgMPnY
-
We present Dr. Puttaswamy (Australia) discussing the advantages offered by innovative inner branch technology (iBEVAR™) versus conventional fenestrations (FEVAR) and outer branches in complex anatomical configurations treatment, angulated visceral segment disease, dissections, and a narrowed aorta. Learn more: https://ibevar.com/ #ArtivionAPAC #TAAA #iBEVAR
-
In July, PSU Songkhla conducted a TAAA workshop on Inner Branch Technology (iBEVAR) with Enside. Experienced surgeons from Singapore, Malaysia, and Thailand attended the workshop to share their case experiences and discuss the best approach to treating patients with this innovative new technology that simplifies the complex TAAA procedure and ensures better patient outcomes. Thank you, @Prince Songkhla University Hospital, for allowing us access to your exceptional facilities. Dr. Boonprasit Kritpracha, Dr. Wittawat Tantarattanapong, Dr. Supong Worathanmanon: you have been a beacon in the region sharing your knowledge and experience! We are advancing aortic technologies with purpose. #ArtivionAPAC #TAAA #Endovascular
-
We are delighted to have Dr. Puttaswamy (Australia) discussing his initial experience with Artivion’s inner branch technology (iBEVAR™) in treating very complex aortic disease. #ArtivionAPAC #TAAA #iBEVAR
-
Congratulations to Dr. Chang Jui-Chih and his team in Hualien Tzu Chi Hospital for implanting the 𝐟𝐢𝐫𝐬𝐭 𝐄-𝐯𝐢𝐭𝐚® 𝐎𝐩𝐞𝐧 𝐍𝐞𝐨 𝐇𝐲𝐛𝐫𝐢𝐝 𝐒𝐭𝐞𝐧𝐭 𝐆𝐫𝐚𝐟𝐭 𝐒𝐲𝐬𝐭𝐞𝐦 𝐢𝐧 𝐓𝐚𝐢𝐰𝐚𝐧. This new achievement marks another milestone in advancing aortic technologies with purpose together. Special thank you to: Prof. Randolph H.L. Wong from Prince of Wales Hospital Hong Kong, for your proctorship and help! And a big thank you to our Artivion team for the great collaboration: David C., Louisa Kong, Gary Tsai. Learn more at: https://lnkd.in/dc6zn8SC #ArtivionAPAC #cardiacsurgery #FET
-
Cultural and social initiatives are integral to Artivion's success. This is reflected in the Day of Purpose, where our APAC employees give their time and efforts to causes and charities they care about. This is a great opportunity to give back to the communities in which we operate, making an impact designing a brighter future. Watch the video below to see how we spent this day. #ArtivionAPAC
-
Prof Randolph Wong (HK) speaks about the E-vita Open Neo study and its outcomes compared to other global #FET study. Please let us know your thoughts on the data. #ArtivionAPAC #cardiacsurgery
-
When you join us at Artivion APAC, you’ll do work that changes lives, and be part of a team that values performance, quality, and innovation. Whatever the challenge, we come together to deliver innovative aortic technologies of unsurpassed quality. We do this leaning in and bringing out the best in others. Apply now to join the team! - Territory Sales Manager, Taiwan: https://lnkd.in/dkhc-SfA - Sales Manager, Malaysia: https://lnkd.in/dtHe-J_d - Territory Sales Manager, Western Australia & South Australia: https://lnkd.in/dD-bXiW3 - Accountant, APAC (Singapore): https://lnkd.in/duUgAJn8 - Accountant, APAC (Thailand): https://lnkd.in/dAm6aCKt - Accountant, APAC (Malaysia): https://lnkd.in/dXRfy4bC - Clinical Sales Specialist, Thailand: https://lnkd.in/dzQQR8-Y - Clinical Manager, Thailand: https://lnkd.in/dyaZrPGF #ArtivionAPAC #Advancingwithpurpose